通过 CpG 和抗 PD-1 抗体的程序性递送来引发炎症的癌症免疫治疗。
Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody.
机构信息
Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, 27695, USA.
Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
出版信息
Adv Mater. 2016 Oct;28(40):8912-8920. doi: 10.1002/adma.201506312. Epub 2016 Aug 25.
Abstract
Inflammation-triggered combination delivery of anti-PD-1 antibody and CpG oligodeoxynucleotides (CpG ODNs) has been demonstrated to prevent cancer relapse utilizing postsurgical inflammatory response. The controlled release of anti-PD1 and CpG ODN by CpG DNA-based "nano-cocoons" can induce considerable immune response, which in turn significantly prolongs the survival time of mice.
摘要
基于 CpG 纳米小囊的 PD-1 抗体和 CpG 寡脱氧核苷酸（CpG ODN）的炎症触发型联合递药已被证明可以利用术后炎症反应预防癌症复发。通过 CpG 基“纳米小囊”的控释可以诱导相当大的免疫反应，从而显著延长小鼠的生存时间。
相似文献
1
Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody.通过 CpG 和抗 PD-1 抗体的程序性递送来引发炎症的癌症免疫治疗。
Adv Mater. 2016 Oct;28(40):8912-8920. doi: 10.1002/adma.201506312. Epub 2016 Aug 25.
2
Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy.基于树突状细胞（DC）的体外疫苗，用低剂量的脂质体抗原和 CpG-ODN 冲击，可改善 PD-1 阻断免疫治疗。
Sci Rep. 2021 Jul 19;11(1):14661. doi: 10.1038/s41598-021-94250-0.
3
Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade.三种 CpG 寡脱氧核苷酸类药物在单药治疗和联合 PD-1 阻断治疗中的抗肿瘤疗效差异。
Pharmacol Res. 2020 Nov;161:105293. doi: 10.1016/j.phrs.2020.105293. Epub 2020 Nov 8.
4
5
Preclinical development of the TLR9 agonist DV281 as an inhaled aerosolized immunotherapeutic for lung cancer: Pharmacological profile in mice, non-human primates, and human primary cells.TLR9 激动剂 DV281 作为肺癌吸入式气溶胶免疫治疗药物的临床前开发：在小鼠、非人灵长类动物和人原代细胞中的药理学特征。
Int Immunopharmacol. 2019 Jan;66:296-308. doi: 10.1016/j.intimp.2018.11.019. Epub 2018 Nov 29.
6
Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system.CpG 寡脱氧核苷酸及其递送系统的结构依赖性免疫刺激作用。
Int J Nanomedicine. 2012;7:2181-95. doi: 10.2147/IJN.S30197. Epub 2012 Apr 27.
7
Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides.刺激性和抑制性寡脱氧核苷酸的免疫治疗效用
Curr Opin Mol Ther. 2004 Apr;6(2):166-74.
8
Oligodeoxynucleotides containing CpG motifs modulate the allergic TH2 response of BALB/c mice to Bet v 1, the major birch pollen allergen.含有CpG基序的寡脱氧核苷酸可调节BALB/c小鼠对主要桦树花粉过敏原Bet v 1的过敏性TH2反应。
J Allergy Clin Immunol. 1999 Nov;104(5):1015-23. doi: 10.1016/s0091-6749(99)70083-7.
9
BN nanospheres functionalized with mesoporous silica for enhancing CpG oligodeoxynucleotide-mediated cancer immunotherapy.用介孔硅功能化 BN 纳米球增强 CpG 寡脱氧核苷酸介导的癌症免疫治疗。
Nanoscale. 2018 Aug 2;10(30):14516-14524. doi: 10.1039/c8nr03820a.
10
Glycogen for lysosome-targeted CpG ODNs delivery and enhanced cancer immunotherapy.用于溶酶体靶向 CpG ODN 传递和增强癌症免疫治疗的糖原。
Int J Biol Macromol. 2024 Feb;257(Pt 1):128536. doi: 10.1016/j.ijbiomac.2023.128536. Epub 2023 Dec 5.
引用本文的文献
1
Hyaluronidase: structure, mechanism of action, diseases and therapeutic targets.透明质酸酶：结构、作用机制、疾病及治疗靶点
Mol Biomed. 2025 Jul 12;6(1):50. doi: 10.1186/s43556-025-00299-y.
2
Stimuli-Responsive DNA Hydrogel Design Strategies for Biomedical Applications.用于生物医学应用的刺激响应性DNA水凝胶设计策略
Biosensors (Basel). 2025 Jun 4;15(6):355. doi: 10.3390/bios15060355.
3
Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer.注入希望：瘤内免疫疗法治疗局部晚期和转移性癌症的潜力
Front Immunol. 2025 Jan 9;15:1479483. doi: 10.3389/fimmu.2024.1479483. eCollection 2024.
4
Recent Review on Biological Barriers and Host-Material Interfaces in Precision Drug Delivery: Advancement in Biomaterial Engineering for Better Treatment Therapies.精准给药中的生物屏障与宿主-材料界面的最新综述：生物材料工程促进更好治疗方法的进展
Pharmaceutics. 2024 Aug 16;16(8):1076. doi: 10.3390/pharmaceutics16081076.
5
NK-92 cells labeled with FeO-PEG-CD56/Avastin@Ce6 nanoprobes for the targeted treatment and noninvasive therapeutic evaluation of breast cancer.用 FeO-PEG-CD56/Avastin@Ce6 纳米探针标记 NK-92 细胞，用于乳腺癌的靶向治疗和无创疗效评估。
J Nanobiotechnology. 2024 Jun 5;22(1):313. doi: 10.1186/s12951-024-02599-x.
6
Recent Advances and Clinical Approach to Cancer Treatment with Nanotechnology Derived Biomolecule.纳米技术衍生生物分子在癌症治疗中的最新进展及临床应用方法
Pharm Nanotechnol. 2024 May 20. doi: 10.2174/0122117385297455240508055620.
7
Autonomous Feedback-Driven Engineered DNAzyme-Coated Trojan Horse-like Nanocapsules for On-Demand CRISPR/Cas9 Delivery.自主反馈驱动工程化 DNA zyme 涂层木马样纳米胶囊用于按需 CRISPR/Cas9 递药。
ACS Nano. 2024 May 28;18(21):13950-13965. doi: 10.1021/acsnano.4c04147. Epub 2024 May 15.
8
Application of Nanomedicine in Tumor Targeting Inflammatory Pathway.纳米医学在肿瘤靶向炎症通路中的应用。
Curr Med Chem. 2025;32(12):2291-2329. doi: 10.2174/0109298673277325231229093344.
9
Intelligent nanomaterials for cancer therapy: recent progresses and future possibilities.用于癌症治疗的智能纳米材料：最新进展与未来可能性
Med Rev (2021). 2023 Sep 20;3(4):321-342. doi: 10.1515/mr-2023-0028. eCollection 2023 Aug.
10
DNA Adjuvant Hydrogel-Optimized Enzymatic Cascade Reaction for Tumor Chemodynamic-Immunotherapy.用于肿瘤化学动力-免疫治疗的DNA佐剂水凝胶优化酶级联反应
Adv Sci (Weinh). 2024 Mar;11(10):e2308229. doi: 10.1002/advs.202308229. Epub 2024 Jan 15.
本文引用的文献
1
Metastasis as an evolutionary process.转移作为一个进化过程。
Science. 2016 Apr 8;352(6282):169-75. doi: 10.1126/science.aaf2784.
2
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition.在检查点抑制时代，癌症免疫疗法的免疫监测的地点、时间和方法。
Clin Cancer Res. 2016 Apr 15;22(8):1865-74. doi: 10.1158/1078-0432.CCR-15-1507.
3
Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling.联合癌症治疗与免疫检查点阻断：干扰素信号的汇聚。
Cell. 2016 Apr 7;165(2):272-5. doi: 10.1016/j.cell.2016.03.031.
4
Enhanced Cancer Immunotherapy by Microneedle Patch-Assisted Delivery of Anti-PD1 Antibody.微针贴片辅助递送抗 PD-1 抗体增强癌症免疫治疗。
Nano Lett. 2016 Apr 13;16(4):2334-40. doi: 10.1021/acs.nanolett.5b05030. Epub 2016 Mar 24.
5
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.用于癌症治疗的PD-L1（B7-H1）和PD-1通路阻断：作用机制、反应生物标志物及联合应用
Sci Transl Med. 2016 Mar 2;8(328):328rv4. doi: 10.1126/scitranslmed.aad7118.
6
Biomaterials for enhancing anti-cancer immunity.用于增强抗癌免疫力的生物材料。
Curr Opin Biotechnol. 2016 Aug;40:1-8. doi: 10.1016/j.copbio.2016.02.001. Epub 2016 Feb 18.
7
Melanoma in 2015: Immune-checkpoint blockade - durable cancer control.2015年黑色素瘤：免疫检查点阻断——持久的癌症控制
Nat Rev Clin Oncol. 2016 Feb;13(2):77-8. doi: 10.1038/nrclinonc.2015.237. Epub 2016 Jan 20.
8
Neutrophil Extracellular Traps Promote the Development and Progression of Liver Metastases after Surgical Stress.中性粒细胞胞外诱捕网促进手术应激后肝转移的发生与进展。
Cancer Res. 2016 Mar 15;76(6):1367-80. doi: 10.1158/0008-5472.CAN-15-1591. Epub 2016 Jan 12.
9
Biomaterials and emerging anticancer therapeutics: engineering the microenvironment.生物材料与新兴抗癌疗法：构建微环境
Nat Rev Cancer. 2016 Jan;16(1):56-66. doi: 10.1038/nrc.2015.3.
10
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.抗程序性死亡蛋白1（PD-1）和抗程序性死亡配体1（PD-L1）免疫检查点抗体的毒性。
Ann Oncol. 2015 Dec;26(12):2375-91. doi: 10.1093/annonc/mdv383. Epub 2015 Sep 14.
Zotero 插件